Extension of esketamine study shows long‐term safety in treatment‐resistant depression

Key Points

• Evaluate the long-term safety of esketamine in treatment-resistant depression.
• Two-year extension of an original trial evaluating esketamine nasal spray in patients with treatment-resistant depression.
• No new safety concerns identified with long-term use of esketamine.
• Overall relapse rate across both studies was 6.9%.